Evaluating Atorvastatin With Omega-3 Fatty Acids in Cardi... | NCT00141232 | Trialant

Evaluating Atorvastatin With Omega-3 Fatty Acids in Cardi... | NCT00141232 | Trialant

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Prim objective (16 wks) for atorvastatin: Proportion of pats. who achieve measured
LDL levels <2.6 mmol/L (<100 mg/dl) Prim object (16 wks) for Omega-3 fatty acid:
Prop of pats. who achieve measured triglycerides <1.5 mmol/L (<200 mg/dl)

Secondary Outcomes

Measure	Description	Time Frame
Prop of pats who achieve LDL levels <2.6 mmol/L (<100 mg/dl) at 52 weeks, taking into account whether the patient received additional atorvastatin therapy or placebo at week 16.
Prop of pats who achieve triglycerides <1.5 mmol/L (<200 mg/dl) at 52 weeks.

Contacts/Locations Module

Ancestor Terms

ID	Term
D011758	Pyrroles
D001393	Azoles
D006573	Heterocyclic Compounds, 1-Ring
D006571	Heterocyclic Compounds
D006538	Heptanoic Acids
D005227	Fatty Acids
D008055	Lipids
D004042	Dietary Fats, Unsaturated
D004041	Dietary Fats
D005223	Fats
D005231	Fatty Acids, Unsaturated
D005395	Fish Oils
D009821	Oils